Log in to your Inderes Free account to see all free content on this page.

Thor Medical

Less than 1K followers

TRMED

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

Thor Medical is a pharmaceutical company. The company specializes in the development of antibody drugs for the treatment of hematological cancer. The greatest specialization is found in precision therapy used in the clinical phase. Other diseases that are treated are non-Hodgkin's lymphoma (NHL). The company was founded in 2009 and is headquartered in Oslo, Norway.

Market cap

-

Turnover

-

Revenue

EBIT %

P/E

Dividend yield-%

Financial calendar

29.8.

2025

Interim report Q2'25

All

Press releases

ShowingAll content types

Regulatory press release4/24/2025, 1:03 PM

Thor Medical ASA: Completion of annual general meeting

Regulatory press release4/11/2025, 4:27 PM

TRMED: Flagging Thor Medical ASA 11 April 2025

Regulatory press release4/9/2025, 1:19 PM

Thor Medical ASA: Notification of trade for close associates of primary insider

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release4/4/2025, 8:52 AM

Thor Medical ASA: Notification of trade for close associates of primary insider

Regulatory press release4/3/2025, 6:38 AM

Thor Medical ASA - Notice of Annual General Meeting on 24 April 2025

Regulatory press release3/28/2025, 6:00 AM

TRMED: Thor Medical ASA publishes Annual report 2024

Regulatory press release3/25/2025, 3:46 PM

Thor Medical makes final investment decision for AlphaOne - ready for commercial production in 2026

Regulatory press release2/26/2025, 6:00 AM

Thor Medical ASA interim and full-year 2024 results - closing in on commercial launch

Regulatory press release2/20/2025, 7:00 AM

TRMED: Invitation to presentation of Thor Medical ASA's second half and full year results 2024

Regulatory press release2/10/2025, 8:25 AM

Thor Medical ASA: Share capital increase in relation to Subsequent Offering registered

Regulatory press release1/24/2025, 7:17 PM

Thor Medical ASA: Notification of trade for close associate of primary insider

Regulatory press release1/24/2025, 7:00 PM

Thor Medical ASA: Final results of the Subsequent Offering

Regulatory press release1/24/2025, 6:00 AM

Thor Medical ASA: The Subscription Period in the Subsequent Offering ends today at 12:30 CET

Regulatory press release1/16/2025, 3:27 PM

TRMED: Financial calendar

Regulatory press release1/15/2025, 9:31 AM

Thor Medical ASA: Share capital increase in relation to Tranche 2 of the Private Placement is registered

Regulatory press release1/13/2025, 6:00 AM

Thor Medical ASA: Commencement of the subscription period for the subsequent offering

Regulatory press release1/10/2025, 12:30 PM

Thor Medical ASA: Approval of prospectus and launch of subsequent offering

Regulatory press release1/7/2025, 6:45 AM

TRMED: Thor Medical secures NOK 90 million loan from Innovation Norway, ensuring full financing of AlphaOne

Regulatory press release12/20/2024, 2:06 PM

Thor Medical ASA: Notification of trade for close associate of primary insider

Regulatory press release12/20/2024, 1:26 PM

Thor Medical ASA: Disclosure of large shareholding

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.